United States
Canada
Mexico
China
Middle East
Japan
Europe
Sales
Marketing
About Us
About Us
Management and Advisors
OUR MEDICAL STUDIES
Our Drug Pipeline
Our Drug Pipeline
PULMONARY FIBROSIS TREATMENT®
COVID-19 TREATMENT®
COVID-19 LONG HAULERS TREATMENT®
FLU TREATMENT®
UNMET NEEDS BREATHING TREATMENT®
NON-STEROIDAL COPD NASAL SPRAY®
70% LOWER STEROID COPD®
NON-STEROIDAL ALZHEIMER’S NASAL SPRAY®
CONCUSSIONS TREATMENT®
DRUG FREE CANCER PRE-TREATMENT®
SMOKING CESSATION ORAL SPRAY®
Conditions We Can Treat
HYPOXEMIA
PULMONARY FIBROSIS
COVID-19
COVID LONG HAULERS
FLU
ASTHMA
COPD
EMPHYSEMA
SARCOIDOSIS
CYSTIC FIBROSIS (CF)
CHRONIC BRONCHITIS
INTERSTITIAL LUNG DISEASE
VIRAL and BACTERIAL Infections
FDA Submissions
REGULATION OF NITRIC OXIDE
SODIUM PYRUVATE
N115 FDA SUBMISSIONS
Contact Us
Investor Relations
Partnerships
News/Press/Blog
Emphycorp News & Peer Reviewed Articles
PRESS RELEASES
Blog
NEW PULMONARY FIBROSIS TREATMENT
United States
Canada
Mexico
China
Middle East
Japan
Europe
Sales
Marketing
Blog
Blog
Home
Archive by Category "Blog"
Blog
Show all
Uncategorized
Medical News
November 7, 2021
EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis
by Emphycorp
by Emphycorp
Privacy Preference Center
Privacy Preferences
